Calidi Biotherapeutics, Inc.
CLDI- Exchange
- NYSE
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001855485
No open-market purchases or sales by Calidi Biotherapeutics, Inc. insiders were filed in the last 90 days; 23 institutions reported holding it in 13F filings for Q2 2026, worth $89.3K in total; no superinvestor holds it.
Other share classesCLDWW
Q1 2022 vs. Q4 2021
How the institutions holding Calidi Biotherapeutics, Inc. changed between Q4 2021 and Q1 2022.
All holders in Q1 2022All holders in Q4 2021
| Measure | Q4 2021 | Q1 2022 | Change |
|---|---|---|---|
| Holders | 27 | 40 | +13 |
| Shares | 16.8M | 20.5M | +3.69M (+22.0%) |
| Value | $164.7M | $202.4M | +$37.7M (+22.9%) |
New holders (13)
Institutions that held Calidi Biotherapeutics, Inc. at the end of Q1 2022 but not at the end of Q4 2021.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Aristeia Capital LLC | 990,000 | $9.79M | 0.18% |
| Millennium Management LLC | 494,801 | $4.89M | 0.01% |
| Nomura Holdings Inc | 185,636 | $1.83M | 0.01% |
| Rpo LLC | 174,392 | $1.72M | 0.59% |
| Centiva Capital, LP | 174,020 | $1.72M | 0.10% |
| Blackstone Group Inc. | 170,842 | $1.69M | 0.00% |
| Bank of Montreal | 100,000 | $987.0K | 0.00% |
| Boothbay Fund Management, LLC | 87,198 | $862.0K | 0.03% |
| Prelude Capital Management, LLC | 60,100 | $594.0K | 0.03% |
| Arena Investors LP | 35,123 | $347.0K | 0.23% |
| Schonfeld Strategic Advisors LLC | 27,320 | $270.0K | 0.00% |
| Old Mission Capital LLC | 26,775 | $265.0K | 0.01% |
| Cohanzick Management, LLC | 2,550 | $25.0K | 0.01% |
Sold out (0)
Institutions that held Calidi Biotherapeutics, Inc. at the end of Q4 2021 and filed for Q1 2022 without it.
None.